BMS-906024 + 5-fluorouracil + leucovorin + irinotecan

This is an **investigational combination regimen** consisting of **BMS-906024**, a potent, selective, orally bioavailable gamma-secretase inhibitor (GSI) that blocks activation of all four Notch receptors (pan-Notch inhibition)[1][2][4], together with three established chemotherapy agents—**5-fluorouracil** (a thymidylate synthase inhibitor), **leucovorin** (a folinic acid used to enhance 5-fluorouracil's activity), and **irinotecan** (a topoisomerase I inhibitor). BMS-906024 is being studied for its capacity to **sensitize solid tumors to cytotoxic chemotherapy**, particularly in tumors with wildtype KRAS and BRAF. The rationale for the combination is the potential for BMS-906024 to enhance cancer cell death and overcome chemotherapy resistance mediated through the Notch signaling axis. This combination is being evaluated primarily in solid tumors, including colorectal and lung cancers[1][2].